Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cabozantinib versus everolimus in advanced renal cell carcinoma</title><author><name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K." last="Choueiri">Toni K. Choueiri</name></author><author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name></author><author><name sortKey="Powles, Thomas" sort="Powles, Thomas" uniqKey="Powles T" first="Thomas" last="Powles">Thomas Powles</name></author><author><name sortKey="Mainwaring, Paul" sort="Mainwaring, Paul" uniqKey="Mainwaring P" first="Paul" last="Mainwaring">Paul Mainwaring</name></author><author><name sortKey="Rini, Brian I" sort="Rini, Brian I" uniqKey="Rini B" first="Brian I." last="Rini">Brian I. Rini</name></author><author><name sortKey="Donskov, Frede" sort="Donskov, Frede" uniqKey="Donskov F" first="Frede" last="Donskov">Frede Donskov</name></author><author><name sortKey="Hammers, Hans" sort="Hammers, Hans" uniqKey="Hammers H" first="Hans" last="Hammers">Hans Hammers</name></author><author><name sortKey="Hutson, Thomas E" sort="Hutson, Thomas E" uniqKey="Hutson T" first="Thomas E." last="Hutson">Thomas E. Hutson</name></author><author><name sortKey="Lee, Jae Lyun" sort="Lee, Jae Lyun" uniqKey="Lee J" first="Jae-Lyun" last="Lee">Jae-Lyun Lee</name></author><author><name sortKey="Peltola, Katriina" sort="Peltola, Katriina" uniqKey="Peltola K" first="Katriina" last="Peltola">Katriina Peltola</name></author><author><name sortKey="Roth, Bruce J" sort="Roth, Bruce J" uniqKey="Roth B" first="Bruce J." last="Roth">Bruce J. Roth</name></author><author><name sortKey="Bjarnason, Georg A" sort="Bjarnason, Georg A" uniqKey="Bjarnason G" first="Georg A." last="Bjarnason">Georg A. Bjarnason</name></author><author><name sortKey="Geczi, Lajos" sort="Geczi, Lajos" uniqKey="Geczi L" first="Lajos" last="Géczi">Lajos Géczi</name></author><author><name sortKey="Keam, Bhumsuk" sort="Keam, Bhumsuk" uniqKey="Keam B" first="Bhumsuk" last="Keam">Bhumsuk Keam</name></author><author><name sortKey="Moroto, Pablo" sort="Moroto, Pablo" uniqKey="Moroto P" first="Pablo" last="Moroto">Pablo Moroto</name></author><author><name sortKey="Heng, Daniel Y C" sort="Heng, Daniel Y C" uniqKey="Heng D" first="Daniel Y. C." last="Heng">Daniel Y. C. Heng</name></author><author><name sortKey="Schmidinger, Manuela" sort="Schmidinger, Manuela" uniqKey="Schmidinger M" first="Manuela" last="Schmidinger">Manuela Schmidinger</name></author><author><name sortKey="Kantoff, Philip W" sort="Kantoff, Philip W" uniqKey="Kantoff P" first="Philip W." last="Kantoff">Philip W. Kantoff</name></author><author><name sortKey="Borgman, Anne" sort="Borgman, Anne" uniqKey="Borgman A" first="Anne" last="Borgman">Anne Borgman</name></author><author><name sortKey="Hessel, Colin" sort="Hessel, Colin" uniqKey="Hessel C" first="Colin" last="Hessel">Colin Hessel</name></author><author><name sortKey="Scheffold, Christian" sort="Scheffold, Christian" uniqKey="Scheffold C" first="Christian" last="Scheffold">Christian Scheffold</name></author><author><name sortKey="Schwab, Gisela M" sort="Schwab, Gisela M" uniqKey="Schwab G" first="Gisela M." last="Schwab">Gisela M. Schwab</name></author><author><name sortKey="Tannir, Nizar M" sort="Tannir, Nizar M" uniqKey="Tannir N" first="Nizar M." last="Tannir">Nizar M. Tannir</name></author><author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J." last="Motzer">Robert J. Motzer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26406150</idno><idno type="pmc">5024539</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539</idno><idno type="RBID">PMC:5024539</idno><idno type="doi">10.1056/NEJMoa1510016</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">001C82</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001C82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Cabozantinib versus everolimus in advanced renal cell carcinoma</title><author><name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K." last="Choueiri">Toni K. Choueiri</name></author><author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name></author><author><name sortKey="Powles, Thomas" sort="Powles, Thomas" uniqKey="Powles T" first="Thomas" last="Powles">Thomas Powles</name></author><author><name sortKey="Mainwaring, Paul" sort="Mainwaring, Paul" uniqKey="Mainwaring P" first="Paul" last="Mainwaring">Paul Mainwaring</name></author><author><name sortKey="Rini, Brian I" sort="Rini, Brian I" uniqKey="Rini B" first="Brian I." last="Rini">Brian I. Rini</name></author><author><name sortKey="Donskov, Frede" sort="Donskov, Frede" uniqKey="Donskov F" first="Frede" last="Donskov">Frede Donskov</name></author><author><name sortKey="Hammers, Hans" sort="Hammers, Hans" uniqKey="Hammers H" first="Hans" last="Hammers">Hans Hammers</name></author><author><name sortKey="Hutson, Thomas E" sort="Hutson, Thomas E" uniqKey="Hutson T" first="Thomas E." last="Hutson">Thomas E. Hutson</name></author><author><name sortKey="Lee, Jae Lyun" sort="Lee, Jae Lyun" uniqKey="Lee J" first="Jae-Lyun" last="Lee">Jae-Lyun Lee</name></author><author><name sortKey="Peltola, Katriina" sort="Peltola, Katriina" uniqKey="Peltola K" first="Katriina" last="Peltola">Katriina Peltola</name></author><author><name sortKey="Roth, Bruce J" sort="Roth, Bruce J" uniqKey="Roth B" first="Bruce J." last="Roth">Bruce J. Roth</name></author><author><name sortKey="Bjarnason, Georg A" sort="Bjarnason, Georg A" uniqKey="Bjarnason G" first="Georg A." last="Bjarnason">Georg A. Bjarnason</name></author><author><name sortKey="Geczi, Lajos" sort="Geczi, Lajos" uniqKey="Geczi L" first="Lajos" last="Géczi">Lajos Géczi</name></author><author><name sortKey="Keam, Bhumsuk" sort="Keam, Bhumsuk" uniqKey="Keam B" first="Bhumsuk" last="Keam">Bhumsuk Keam</name></author><author><name sortKey="Moroto, Pablo" sort="Moroto, Pablo" uniqKey="Moroto P" first="Pablo" last="Moroto">Pablo Moroto</name></author><author><name sortKey="Heng, Daniel Y C" sort="Heng, Daniel Y C" uniqKey="Heng D" first="Daniel Y. C." last="Heng">Daniel Y. C. Heng</name></author><author><name sortKey="Schmidinger, Manuela" sort="Schmidinger, Manuela" uniqKey="Schmidinger M" first="Manuela" last="Schmidinger">Manuela Schmidinger</name></author><author><name sortKey="Kantoff, Philip W" sort="Kantoff, Philip W" uniqKey="Kantoff P" first="Philip W." last="Kantoff">Philip W. Kantoff</name></author><author><name sortKey="Borgman, Anne" sort="Borgman, Anne" uniqKey="Borgman A" first="Anne" last="Borgman">Anne Borgman</name></author><author><name sortKey="Hessel, Colin" sort="Hessel, Colin" uniqKey="Hessel C" first="Colin" last="Hessel">Colin Hessel</name></author><author><name sortKey="Scheffold, Christian" sort="Scheffold, Christian" uniqKey="Scheffold C" first="Christian" last="Scheffold">Christian Scheffold</name></author><author><name sortKey="Schwab, Gisela M" sort="Schwab, Gisela M" uniqKey="Schwab G" first="Gisela M." last="Schwab">Gisela M. Schwab</name></author><author><name sortKey="Tannir, Nizar M" sort="Tannir, Nizar M" uniqKey="Tannir N" first="Nizar M." last="Tannir">Nizar M. Tannir</name></author><author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J." last="Motzer">Robert J. Motzer</name></author></analytic><series><title level="j">The New England journal of medicine</title><idno type="ISSN">0028-4793</idno><idno type="eISSN">1533-4406</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title><p id="P1">Cabozantinib is an oral small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL; each has been implicated in metastatic renal cell carcinoma (RCC) pathobiology or development of resistance to antiangiogenic drugs. This randomized open-label phase 3 trial evaluated the efficacy of cabozantinib compared to everolimus in RCC patients who progressed after VEGFR-targeted therapy.</p></sec><sec id="S2"><title>Methods</title><p id="P2">The trial randomized 658 patients to receive cabozantinib at a dose of 60 mg daily, or everolimus at a dose of 10 mg daily. The primary endpoint was progression-free survival. Secondary efficacy endpoints were overall survival and objective response rate.</p></sec><sec id="S3"><title>Results</title><p id="P3">Median progression-free survival was 7.4 months with cabozantinib and 3.8 months with everolimus. The risk of progression or death was 42% lower with cabozantinib compared to everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P < 0.001). Objective response rates were 21% with cabozantinib and 5% with everolimus (P < 0.001). A planned interim analysis showed that overall survival was improved with cabozantinib (hazard ratio, 0.67; 95% CI, 0.51 to 0.89; P = 0.005) but did not cross the significance boundary. Adverse events (grade 3 or 4, regardless of causality) were reported in 74% of cabozantinib patients and 65% of everolimus patients. Discontinuation of study treatment for adverse events occurred in 9.1% of cabozantinib patients and 10% of everolimus patients.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Cabozantinib improved progression-free survival compared to everolimus in RCC patients who progressed after VEGFR-targeted therapy.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">0255562</journal-id><journal-id journal-id-type="pubmed-jr-id">5985</journal-id><journal-id journal-id-type="nlm-ta">N Engl J Med</journal-id><journal-id journal-id-type="iso-abbrev">N. Engl. J. Med.</journal-id><journal-title-group><journal-title>The New England journal of medicine</journal-title></journal-title-group><issn pub-type="ppub">0028-4793</issn><issn pub-type="epub">1533-4406</issn></journal-meta><article-meta><article-id pub-id-type="pmid">26406150</article-id><article-id pub-id-type="pmc">5024539</article-id><article-id pub-id-type="doi">10.1056/NEJMoa1510016</article-id><article-id pub-id-type="manuscript">NIHMS768250</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cabozantinib versus everolimus in advanced renal cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Choueiri</surname><given-names>Toni K.</given-names></name><degrees>M.D.</degrees><aff id="A1">Dana Farber Cancer Institute, Boston, MA</aff></contrib><contrib contrib-type="author"><name><surname>Escudier</surname><given-names>Bernard</given-names></name><degrees>M.D.</degrees><aff id="A2">Institut Gustave Roussy, Villejuif, France</aff></contrib><contrib contrib-type="author"><name><surname>Powles</surname><given-names>Thomas</given-names></name><degrees>M.D.</degrees><aff id="A3">Barts Cancer Institute, London, UK</aff></contrib><contrib contrib-type="author"><name><surname>Mainwaring</surname><given-names>Paul</given-names></name><degrees>M.D.</degrees><aff id="A4">ICON Cancer Care, South Brisbane, Australia</aff></contrib><contrib contrib-type="author"><name><surname>Rini</surname><given-names>Brian I.</given-names></name><degrees>M.D.</degrees><aff id="A5">Cleveland Clinic, Cleveland, OH</aff></contrib><contrib contrib-type="author"><name><surname>Donskov</surname><given-names>Frede</given-names></name><degrees>M.D., Ph.D.</degrees><aff id="A6">Aarhus University Hospital, Aarhus, Denmark</aff></contrib><contrib contrib-type="author"><name><surname>Hammers</surname><given-names>Hans</given-names></name><degrees>M.D., Ph.D.</degrees><aff id="A7">Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD</aff></contrib><contrib contrib-type="author"><name><surname>Hutson</surname><given-names>Thomas E.</given-names></name><degrees>D.O.</degrees><aff id="A8">Baylor Sammons Cancer Center–Texas Oncology, Dallas, TX</aff></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jae-Lyun</given-names></name><degrees>M.D., Ph.D.</degrees><aff id="A9">University of Ulsan College of Medicine, Seoul, Korea</aff></contrib><contrib contrib-type="author"><name><surname>Peltola</surname><given-names>Katriina</given-names></name><degrees>M.D., Ph.D.</degrees><aff id="A10">Helsinki University Central Hospital Cancer Center, Helsinki, Finland</aff></contrib><contrib contrib-type="author"><name><surname>Roth</surname><given-names>Bruce J.</given-names></name><degrees>M.D.</degrees><aff id="A11">Washington University, St. Louis, MO</aff></contrib><contrib contrib-type="author"><name><surname>Bjarnason</surname><given-names>Georg A.</given-names></name><degrees>M.D.</degrees><aff id="A12">Sunnybrook Odette Cancer Centre, Toronto, Canada</aff></contrib><contrib contrib-type="author"><name><surname>Géczi</surname><given-names>Lajos</given-names></name><degrees>M.D., Ph.D.</degrees><aff id="A13">National Institute of Oncology, Budapest, Hungary</aff></contrib><contrib contrib-type="author"><name><surname>Keam</surname><given-names>Bhumsuk</given-names></name><degrees>M.D., Ph.D.</degrees><aff id="A14">Seoul National University Hospital, Seoul, Korea</aff></contrib><contrib contrib-type="author"><name><surname>Moroto</surname><given-names>Pablo</given-names></name><degrees>M.D.</degrees><aff id="A15">Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</aff></contrib><contrib contrib-type="author"><name><surname>Heng</surname><given-names>Daniel Y. C.</given-names></name><degrees>M.D., M.P.H</degrees><aff id="A16">Tom Baker Cancer Centre, Calgary, Canada</aff></contrib><contrib contrib-type="author"><name><surname>Schmidinger</surname><given-names>Manuela</given-names></name><degrees>M.D.</degrees><aff id="A17">Medical University of Vienna, Vienna, Austria</aff></contrib><contrib contrib-type="author"><name><surname>Kantoff</surname><given-names>Philip W.</given-names></name><degrees>M.D.</degrees><aff id="A18">Dana Farber Cancer Institute, Boston, MA</aff></contrib><contrib contrib-type="author"><name><surname>Borgman</surname><given-names>Anne</given-names></name><degrees>M.D.</degrees><aff id="A19">Exelixis, Inc., South San Francisco, CA</aff></contrib><contrib contrib-type="author"><name><surname>Hessel</surname><given-names>Colin</given-names></name><degrees>M.S.</degrees><aff id="A20">Exelixis, Inc., South San Francisco, CA</aff></contrib><contrib contrib-type="author"><name><surname>Scheffold</surname><given-names>Christian</given-names></name><degrees>M.D., Ph.D.</degrees><aff id="A21">Exelixis, Inc., South San Francisco, CA</aff></contrib><contrib contrib-type="author"><name><surname>Schwab</surname><given-names>Gisela M.</given-names></name><degrees>M.D.</degrees><aff id="A22">Exelixis, Inc., South San Francisco, CA</aff></contrib><contrib contrib-type="author"><name><surname>Tannir</surname><given-names>Nizar M.</given-names></name><degrees>M.D.</degrees><aff id="A23">University of Texas MD Anderson Cancer Center, Houston, TX</aff></contrib><contrib contrib-type="author"><name><surname>Motzer</surname><given-names>Robert J.</given-names></name><degrees>M.D.</degrees><aff id="A24">Memorial Sloan-Kettering Cancer Center, New York, NY</aff></contrib><contrib contrib-type="author"><collab>for the METEOR Investigators</collab><xref rid="FN2" ref-type="author-notes">*</xref></contrib></contrib-group><author-notes><corresp id="FN1"><bold>Corresponding author:</bold> Toni K. Choueiri, M.D., 450 Brookline Ave. (DANA 1230), Boston, MA 02215, Phone: 617-632-5456, Fax: 617-632-2165, <email>Toni_Choueiri@dfci.harvard.edu</email></corresp><fn id="FN2"><label>*</label><p>A complete list of investigators in the METEOR trial is provided in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Appendix</xref>.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>9</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>25</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="ppub"><day>5</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>9</month><year>2016</year></pub-date><volume>373</volume><issue>19</issue><fpage>1814</fpage><lpage>1823</lpage><pmc-comment>elocation-id from pubmed: 10.1056/NEJMoa1510016</pmc-comment>
<abstract><sec id="S1"><title>Background</title><p id="P1">Cabozantinib is an oral small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL; each has been implicated in metastatic renal cell carcinoma (RCC) pathobiology or development of resistance to antiangiogenic drugs. This randomized open-label phase 3 trial evaluated the efficacy of cabozantinib compared to everolimus in RCC patients who progressed after VEGFR-targeted therapy.</p></sec><sec id="S2"><title>Methods</title><p id="P2">The trial randomized 658 patients to receive cabozantinib at a dose of 60 mg daily, or everolimus at a dose of 10 mg daily. The primary endpoint was progression-free survival. Secondary efficacy endpoints were overall survival and objective response rate.</p></sec><sec id="S3"><title>Results</title><p id="P3">Median progression-free survival was 7.4 months with cabozantinib and 3.8 months with everolimus. The risk of progression or death was 42% lower with cabozantinib compared to everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P < 0.001). Objective response rates were 21% with cabozantinib and 5% with everolimus (P < 0.001). A planned interim analysis showed that overall survival was improved with cabozantinib (hazard ratio, 0.67; 95% CI, 0.51 to 0.89; P = 0.005) but did not cross the significance boundary. Adverse events (grade 3 or 4, regardless of causality) were reported in 74% of cabozantinib patients and 65% of everolimus patients. Discontinuation of study treatment for adverse events occurred in 9.1% of cabozantinib patients and 10% of everolimus patients.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Cabozantinib improved progression-free survival compared to everolimus in RCC patients who progressed after VEGFR-targeted therapy.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C820 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001C820 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |